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Abstract: Metronomic agents reduce the effective doses and adverse effects of cytostatics in cancer
chemotherapy. Therefore, they can enhance the treatment efficiency of drug-resistant cancers.
Cytostatic and anti-angiogenic effects of fenofibrate (FF) suggest that it can be used for the metronomic
chemotherapy of drug-resistant prostate tumors. To estimate the effect of FF on the drug-resistance of
prostate cancer cells, we compared the reactions of naïve and drug-resistant cells to the combined
treatment with docetaxel (DCX)/mitoxantrone (MTX) and FF. FF sensitized drug-resistant DU145
and PC3 cells to DCX and MTX, as illustrated by their reduced viability and invasive potential
observed in the presence of DCX/MTX and FF. The synergy of the cytostatic activities of both agents
was accompanied by the inactivation of P-gp-dependent efflux, dysfunction of the microtubular
system, and induction of polyploidy in DCX-resistant cells. Chemical inhibition of PPARα- and
reactive oxygen species (ROS)-dependent pathways by GW6471 and N-acetyl-L-cysteine, respectively,
had no effect on cell sensitivity to combined DCX/FF treatment. Instead, we observed the signs
of adenosine triphosphate (ATP) deficit and autophagy in DCX/FF-treated drug-resistant cells.
Furthermore, the cells that had been permanently propagated under DCX- and DCX/FF-induced
stress did not acquire DCX/FF-resistance. Instead, relatively slow proliferation of DCX-resistant
cells was efficiently inhibited by FF. Collectively, our observations show that FF reduces the effective
doses of DCX by interfering with the drug resistance and energy metabolism of prostate cancer
cells. Concomitantly, it impairs the chemotherapy-induced microevolution and expansion of
DCX/FF-resistant cells. Therefore, FF can be applied as a metronomic agent to enhance the efficiency
of palliative chemotherapy of prostate cancer.
Keywords: fenofibrate; chemotherapy; prostate cancer; drug-resistance; cancer microevolution
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1. Introduction
Versatile self-defense/protective systems are functional in prokaryotic and eukaryotic cells.
They reduce cellular susceptibility to adverse environmental conditions and to chemical pathogens.
In metazoa, multi-drug resistance (MDR) systems preserve the tissue and organ homeostasis by
mediating the efflux of chemical pathogens, enhancing the drug metabolism and DNA repair,
and elevating autophagy in intoxicated cells [1]. Impaired MDR negatively affects the cells’
microenvironmental adaptability but the over-activity of MDR pathways can interfere with the
cytostatic activity of chemotherapeutics. For instance, the activation of self-defense systems in bacteria
and fungi reduces the efficiency of antibiotic therapies, whereas the efficiency of cancer chemotherapy is
impaired by over-active MDR systems in cancer cells [2]. The activity of membrane proteins that pump
chemicals out of the cells and reduce the intracellular levels of chemotherapeutic agents is perhaps the
most prominent MDR system in cancer cells; however, the activity of other self-defense systems is also
augmented in cancer cells. For instance, DNA repair systems and autophagy of damaged organelles
additionally augments the drug-resistance of cancer cells. Along with the formation of invasive cancer
cell sub-populations, these events collectively lead to the ultimate recurrence of malignant tumors
after temporary cancer remission [3]. Thus, drug-resistance of cancer cells remains a major challenge
in current clinical oncology [1].
Prolonged administration of chemotherapeutic drugs promotes the “survival of the fittest”
cells [4], leading to the selective intratumoral microevolution/expansion of drug-resistant cell lineages.
Their expansion in primary tumors eventually results in tumor recurrence after the cessation of
chemotherapy. Functional links exist between multi-drug resistance, multipotency and malignancy of
cancer cells. For instance, cancer stem cells (CSCs; [5,6]) are characterized by high activity of drug-efflux
systems [7,8], which facilitates their survival upon exposition to the long-term chemotherapeutic stress,
and underlies subsequent tumor recurrence and metastasis [9,10]. These systems are also over-active
in cancer cells that have undergone epithelial-mesenchymal transition (EMT). This leads to enhanced
drug-resistance of the cells that constitute the invasive front(s) of tumors [11–13], including prostate
cancer, which is a leading cause of cancer-related deaths in Western countries. So far, ca. 50 MDR
proteins has been identified [7]. Over-activation of at least 3 proteins (ABCB1, ABCC1 i ABCG2) was
observed in post-EMT prostate cancer cells [14]. The interrelations between the malignancy and the
activity of MDR systems in prostate cancer cells enforce the gradual increase of chemotherapeutic
doses against continuously more aggressive tumor cells that reside within the weakening organism of
the patient. The dreadful effects of this vicious cycle are especially significant in palliative treatment
of older patients, who are over-sensitive to the adverse effects of chemotherapeutics. These effects
enforce premature cessations of treatment, which facilitate the expansion of invasive drug-resistant
cells, and prostate tumor recurrence and progression.
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The way out of this dilemma is provided by metronomic agents that interfere with
the drug-resistance and malignancy of cancer cells, thus reducing the effective doses of
chemotherapeutics [15]. Recently, the application of fenofibrate (FF; propan-2-yl 2-{4-[(4-chlorophenyl)
carbonyl]phenoxy}-2-methylpropanoate) has been suggested for cancer treatment [16,17] including
the palliative strategies of prostate chemotherapy [18,19]. FF is a well-tolerated, Food and Drug
Administration (FDA)-approved anti-hyperlipidemic and vasoactive drug, which lowers serum levels
of triglycerides and cholesterol, and improves the low-density lipoprotein:high-density lipoprotein
(LDL:HDL) ratio [20]. PPARα-dependent and PPARα-independent signaling is involved in cancer
cell reactions to FF; however, the interference of FF with the chemoresistance of cancer cells has
not yet been analyzed. We hypothesized that FF can increase the sensitivity of prostate cancer cells
to chemotherapeutics, thus increasing their efficiency and attenuating systemic adverse effects of
chemotherapy. To verify this notion, we analyzed the synergy of cytostatic and anti-invasive effects of
docetaxel (DCX), mitoxantrone (MTX) and FF on drug-resistant prostate cancer cells. Furthermore,
we evaluated the interference of FF with their multi-drug resistance systems. Finally, we focused
on self-protective mechanisms, which are activated by prostate cancer cells in response to combined
DCX/FF treatment. Our data show that FF can reduce the effective doses of DCX in the therapy of
prostate cancer.
2. Results
2.1. Fenofibrate (FF) Increases the Sensitivity of DU145 Cells to Docetaxel (DCX)
The additive inhibitory effects of combined docetaxel (DCX)/fenofibrate (FF) treatment on the
welfare of prostate cancer cells are illustrated by the inhibition of naïve DU145 cell motility observed
immediately after the administration of both agents (Figure 1A). A less-pronounced inhibition of
DU145 cell motility and displacement was observed, when DCX and FF were administered separately;
however FF efficiently attenuated gap junctional intercellular communication (GJIC) in DU145
populations after 24 h-long treatment (Figure S1A). These effects were followed by prominent actin
cytoskeleton rearrangements in DCX- and DCX/FF-treated cells (Figure 1B) and correlated with a
dose-dependent inhibitory effect of DCX and FF on DU145 proliferation (Figure 1C, cf. Figure S1B).
A distinct inhibition of DU145 proliferation was observed when DCX/FF was administered at the
concentration between 1.25 nM/5 µM. Additive effects of DCX/FF on cell motility and proliferation
were also observed in the populations of human prostate cancer PC3 cells (Figure S2A–D). Furthermore,
DNA content analyses revealed the induction of apoptosis and polyploidy in DCX/FF-treated
DU145 populations, as illustrated by the abundance of their sub-G1/supra-G2 fractions, respectively
(Figure 1D). The apoptotic response of DU145 cells to the combined DCX/FF treatment was further
confirmed by AnnexinV/PI assay that showed a prominent fraction of annexinV+ cells after DCX/FF
administration in the absence of a distinct pro-apoptotic activity of separately administered agents
(Figure 1E). Collectively, these data show that FF increases the sensitivity of prostate cancer cells
to DCX.
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localization of actin (red) and vinculin (green) were visualized by immunofluorescence in DU145 cells 
incubated in the presence of DCX/FF (2.5 nM/25 μM) for 48 h. (C) DU145 cells were cultivated in the 
presence of DCX (0.3–5 nM) and/or FF (5–25 μM). Their morphology (upper panel; 2.5 nM DCX/25 μM 
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Figure 1. Additive effects of fenofibrate (FF) and docetaxel (DCX) on the viability and invasive potential
of naïve DU145 cells. (A) Naïve DU145 cells were incubated in the presence of DCX (2.5 nM) and/or FF
(25 µM) and their motility was estimated immediately after drug administration. Cell trajectories are
depicted as circular diagrams (axis scale in µm) drawn with the initial point of each trajectory placed
at the origin of the plot (registered for 6 h; N > 50). Dot-plots and column charts show movement
parameters at the single cell and population level, respectively (plotted as % of control). (B) Intracellular
localization of actin (red) and vinculin (green) were visualized by immunofluorescence in DU145 cells
incubated in the presence of DCX/FF (2.5 nM/25 µM) for 48 h. (C) DU145 cells were cultivated in the
presence of DCX (0.3–5 nM) and/or FF (5–25 µM). Their morphology (upper panel; 2.5 nM DCX/25 µM
FF) and proliferation (lower panel; calculated as % of control) were estimated after 48 h. (D,E) The effect
of t e long-term DCX/FF (2.5 nM/25 µM) treatment on the viability of DU145 cells was estimated with
fluorescence-activated cell sorting (FACS)-assisted DNA content (after 48 h; D) and annexinV/PI assay
(after 72 h; E). DNA histograms and compensated dot-plots comprise 30,000/50,000 events, classified
based on their bright field ratios and/or nuclear contrast. Statistical significance was analyzed with
the non-parametric Mann-Whitney (A; vs. non-treated control (* p ≤ 0.05) or vs. controls indicated by
the backets; # p ≤ 0.05); or by t-Student test (C; vs. non-treated control (* p ≤ 0.05) or vs. DCX-treated
variant (0 µM FF; # p ≤ 0.05). Error bars represent standard error of the mean (SEM). Scale bar: 50 µm
(B) and 100 µm (C). Data are representative of at least three independent experiments (N > 3). Note
that FF increases the sensitivity of DU145 cells to DCX.
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2.2. FF Interferes with DCX-Resistance of Prostate Cancer Cells
To estimate the interference of FF with the drug-resistance of prostate cancer cells, we have
established 2 sub-lines of DCX-resistant DU145 cells (Figure S3; see Section 4 Materials and Methods)
by exposing naïve DU145 cells to increasing doses of DCX.
Drug-resistance of DU145_DCX20 and DU145_DCX50 cells was manifested by negligible effects
of DCX (Figure 2A) and MTX on their proliferation (Figure S4A). DU145_DCX50 cells, which were
pre-selected in the presence of higher DCX concentrations, were slightly more resistant to both
agents than DU145_DCX20 cells (Figure 2A; cf. Figure S4A). Both drug-resistant cell lines displayed
epithelioid phenotype with prominent focal contacts, relatively low proliferation rate (Figure 2B) and
Cx43+ gap junctions (Figure S4B). They were also characterized by a slightly less efficient motility
than DU145 cells (Figure 2C), but relatively high transmigration potential in vitro (Figure 2D; cf.
Figure S4C). In comparison to DU145 tumors, DU145_DCX20 tumors grew relatively slowly in control
in vivo conditions, but were considerably less vulnerable to DCX stress (Figure 2E). DCX-resistance
of DU145_DCX20/50 cells correlated with the high efficiency of efflux systems (ABC transporters)
in these cells, illustrated by a high calcein efflux assay (Figure 2F; cf. Figure S4D). Accordingly, DCX
did not affect their residual GJIC (Figure S4E) and motility in vitro (Figure S5A). FF increased the
susceptibility of DU145_DCX20 cells to DCX (Figure 2G and Figure S5B) and to MTX (Figure S4A)
in a dose-dependent manner. This effect was also manifested by the inhibition of cell motility in
DCX/FF-treated populations (Figure 2H, cf. Figure S5A) and by the additive cytostatic effect of
both agents on the viability of drug-resistant cells. This is illustrated by their decreased viability
(measured by adenosine triphosphate (ATP) levels at the population level) and prolonged doubling
times in the presence of 2.5 nM DCX/25 µM FF (Figure 2I, cf. Figure S5C–E). Notably, DCX/FF also
exerted additive cytostatic effects on drug-resistant PC3 cells, which confirms biological significance
of this phenomenon (cf. Figure S2F–H). These observations show that FF augments the sensitivity of
drug-resistant prostate cancer cells to the cytostatic activity of DCX.
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Figure 2. FF interferes with the DCX-resistance of DU145 cells. (A) Naïve DU145 and DCX-resistant
DU145 cells (DU145_DCX20 and DU145_DCX50; cf. Figure S3 in Supplementary material) were cultivated
in the presence of DCX (1.25–50 nM) and their proliferation was estimated after 48 h. (B) Comparison of
the morphology, actin cytoskeleton architecture (left) and proliferation (right) of DU145, DU145_DCX20
and DU145_DCX50 cells in control conditions. (C,D) Motility (C) and trans-endothelial migration
efficiency of DU145 and DCX-resistant 145 ce ls (D) was estimated in actin/vinculin-stained specimens.
DU145 cells we e additionally stained with CellTr cer Orange CMRA. Transmigration values show a
percent of cancer cells that penetrated the adjacent endothelial barrier. (E) DU145 and DU145_DCX20
cells were subcutaneously injected into severe combined immunodeficient (SCID) mice (1.5 × 105) and
the growth of tumors was estimated in the absence/presence of DCX (20 mg/kg b.w). Images show
the structure of tumors visualized by hematoxilin/eosin staining. (F) The activity of efflux pumps in
DCX-resistant DU145 cells was estimated with calcein efflux assay in control conditions (plotted as
fluorescence in ensity (a.u.)). (G) DU145_DCX20 c lls were cultivated in the presence of DCX (0.3–5 nM)
and/or FF (5–25 µM). Their proliferation was estimated after 48 h (plotted as % of control). (H,I)
Naïve and DCX-resistant DU145 cells were treated with 2.5 nM DCX/25 µM FF and their motility was
estimated with time-lapse videomicroscopy immediately afterwards (H) or (I) their viability (ATP levels
(left)/proliferation (right)) were estimated after 48 h (calculated as % of control). Data representative of
at least three independent experiments (N > 3). St tistical significance was analyzed with the t-Student
(A,B,D–G,I) or with the non-parametric Mann-Whitney test (C,H) v . non-treated c trol (* p ≤ 0.05), vs.
DCX-treated variant (# p ≤ 0.05; A) or vs. the variant indicated by the brackets (# p ≤ 0.05). Error bars
represent SEM. Scale bar: 50 µm. Note the additive inhibitory effects of FF and DCX on the welfare and
motility of DCX-resistant DU145 cells.
2.3. FF Attenuates the Invasive Potential of DCX-Resistant DU145 Cells
Further analyses of the invasive behavior of DCX/FF-treated of prostate cancer cells enabled
us to address the therapeutic significance of the inhibitory FF effect on their DCX-resistance. Not
surprisingly, 2.5 nM DCX had little short-term effect on the displacement of DCX-resistant cells
(Figure 3A; cf. Figure S5A). This is illustrated by relatively high values of this parameter in DCX-treated
DU145_DCX20/50 populations. DCX also exerted minute effects on GJIC in DU145_DCX20
populations, whereas FF treatment considerably impaired this parameter, both in the absence and the
presence of DCX (Figure 3B; cf. Figure S6A). Transendothelial penetration assays demonstrated that
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the inhibitory effect of DCX on the efficiency of transendothelial migration of DCX-resistant DU145
cells was augmented by FF (Figure 3C; cf. Figure S6B). DCX-resistant cells were even more sensitive
to FF treatment than DU145 cells. It also affected polarization of both naïve and DCX-resistant cell
shapes (Figure 3D; cf. Figure S6C) and interfered with their long-term displacement (Figure 3E;
cf. Figure S6D,E). Long-term interference of DCX/FF with actin cytoskeleton architecture and
with displacement of DU145_DCX20/DCX50 cells may account for the impaired transmigration
of DCX-resistant cells. When extrapolated to in vivo situation, these data indicate that FF can interfere
with prostate cancer invasion and systemic dissipation.
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Figure 3. Combined DCX/FF treatment interferes with the invasive behavior of DCX-resistant DU145
cells. (A) Displacement of DU145 and DCX-resistant DU lls was estimated with time-lapse
videomicrosc py immediately fter th administration of DCX ( ) and/or FF (25 µM). Column
bars show averaged cell displacement (registered for 6 h; N > 50). (B) DCX-resistant DU145 cells
were incubated in the presence of 2.5 nM DCX and/or 25 µM FF for 24 h. GJIC was estimated
by calcein transfer assay and calculated as coupling index (left panel) and coupling ratio (right
panel). (C) DU145 and DU145_DCX20 cells were cultivated as in (B) and their transmigration
through HUVEC continuum was estimated by transendothelial migration assay. Transmigration
values show he percent of DU145 cells th t srup ed/pen ted endotheli l layer (upper panel)
or the percent of penetrating DU145_DCX20 cells calculated in relation to the transmigation of
naïve DU145 cells in the corresponding conditions (lower panel). (D,E) Intracellular distribution
of actin/vinculin was visualized in DU145 and DCX-resistant DU145 cells incubated in the presence of
2.5 nM DCX/25 µM FF for 48 h with fluorescence microscopy (D) or cell displacement was estimated
with time-lapse videomicroscopy 48 h after the administration of the drugs (E). Column charts show
movement parameters at the single cell and population level, respectively. Column bars show
averaged cell displacement of the cells cultivated in different conditions (left, measured as % of
control), or calculated in relation to DU145 cell movement (right). Data representative of at least three
independent experiments (N > 3). Error bars represent SEM. Statistical significance was analyzed with
the non-parametric Mann–Whitney test (A,E) or t-Student test (B,C) vs. non-treated control (* p ≤ 0.05)
or vs. the variant indicated by the brackets (# p ≤ 0.05). Scale bars: 50 µm. Note that FF strengthens the
long-term effect of DCX on the invasive potential of DCX-resistant DU145 cells.
Cancers 2019, 11, 77 8 of 21
2.4. FF Inhibits the Activity of Drug-Efflux Pumps in DU145 Cells
The cytostatic and anti-invasive effects of FF on drug-resistant cells prompted us to estimate FF
interference with the activity of their detoxication systems. Tandem mass spectrometry suggested
the elevation of P-gp (ABCB1) levels in DCX-resistant DU145 cells (Figure 4A). The expression of
P-gp was also revealed in naïve DU145 and DU145_DCX20 cells by immunofluorescence studies in
control conditions and in the presence of DCX/FF (Figure 4B). The inhibition of P-gp by elacridar
(0.1 µM) attenuated the calcein efflux from DU145_DCX20 cells to the levels characteristic for DU145
cells (Figure 4C; cf. Figure S7A). FF induced the inhibition of dye efflux in drug-resistant cells, which
corresponded to that observed in the presence of elacridar (Figure 4C). This effect was accompanied
by the disorganization of microtubular systems both in DCX/elacridar- and DCX/FF-treated cells
(Figure 4D, left; cf. Figure S7B, C) and the inhibition of their proliferation (Figure 4D; right).
Notably, the chemical inhibition of ABCC1 (by sulfinpyranoze) and ABCG2 (by fumitremorgin
C) had no significant effect on calcein efflux, even though both agents (especially fumitremorgin C)
significantly inhibited cell proliferation (Figure S7D). Furthermore, elacridar increased the sensitivity
of drug-resistant PC3 cells to DCX (Figure S7E). These observations confirm the dominant role of
P-gp in the determination of DU145/PC3 drug-resistance. They also indicate that FF impairs the
drug-resistance of DU145_DCX20 cells via the interference with P-gp function.
To identify the signaling pathways responsible for the interference of FF with efflux systems, we
applied DCX and FF to naïve DU145 and DU145_DCX20 cells in the presence of chemical PPARα
and reactive oxygen species (ROS) inhibitor (GW6471 and N-acetyl-L-cysteine (NAC), respectively,
Figure 4E). The lack of their attenuating effects on the cytostatic activity of DCX/FF indicates that
FF interferes with their DCX-resistance in a PPARα/ROS-independent manner. On the other hand,
we noticed increased ATP levels in DCX-pretreated DU145_DCX20 cells upon the inhibition of P-gp
activity by elacridar (Figure 4F) and a less pronounced ATP accumulation in DCX/FF-treated cells.
Collectively, these data indicate that FF impairs energy metabolism that interferes with the activity of
P-gp-induced DCX efflux in DCX-resistant DU145 cells.
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Figure 4. FF interferes with the activity of multi-drug resistance (MDR) transporters in DCX-resistant
DU145 cells. (A) Abundance of the peptides identified by shotgun tandem mass spectrometry
corresponding to of MDR protein levels in DU145 and DCX-resistant cells. MDR protein levels in DU145
and their DCX-resistant counterparts cells were identified according to semi-quantitative analysis of
peptide-spectrum matches (PSMs) obtained in liquid chromatography-mass spectrometry LC–MS/MS
measurements. (B) The effect of DCX/FF on the intracellular localization of P-gp was visualized with
fluorescence micr scopy i naïve DU145 and DU145_DCX20 cells 48 h after the administration of 2.5 nM
DCX/25 µM FF. (C) Naïve DU145 and DU145_DCX20 cells were incubated in the presence of elacridar
(0.1 µM) or FF (25 µM). The efficiency of their efflux systems was measured by calcein efflux assay.
(D) The effect of DCX/elacridar/FF on the architecture of microtubules in DU145 and DCX-resistant
DU145 cells (left) and on their proliferation (right) was estimated with immunofluorescence and cell
counting, respectively. (E) Naïve DU145 (left) and DU145_DCX20 cells (right) were incubated in the
presence of DCX/FF and GW6471 (10 µM) or N-acetyl-L-cysteine (1 mM; NAC), and their proliferation
was estimated after 48 h (as % control). (F) The effect of elacridar (0.1 µM) and/or 2.5 nM DCX/25 µM
FF on ATP levels was estimated in single DU145 and DCX-resistant DU145 cells after 48 h of incubation
and calculated as % of the untreated control (left) and as % of DCX/elacridar-treated cells (right).
Data representative of at least three independent experiments (N > 3). Error bars represent SEM.
Statistical significance was analyzed with t-Student test vs. non-treated DU145 control, non-treated
DU145_DCX20 control (E; right; * p ≤0.05) or vs. the variant indicated by the brackets (# p ≤ 0.05).
Scale bar: 50 (D) or 100 µm (B). Note that the DCX-resistance of DU145_DCX20 and DU145_DCX50
cells correlates with relatively high activity of efflux systems in these cells. Inhibition of this system in
DCX/FF-treated cells correlates with PPARα/ROS-independent reduction of intracellular ATP levels.
2.5. Combined DCX/FF Stress Induces Autophagy in DCX-Resistant Cells
Cancer cells activate numerous self-defense systems in response to extrinsic stress. Therefore, we
further estimated whether the activation of stress responses can protect drug-resistant prostate cancer
cells against combined DCX/FF treatment. Apparently, it activated stress reactions of DCX-resistant
cells as illustrated by the increased phosphorylation of AMP-activated kinase (AMPK;not shown).
Concomitantly, 3-methyladenine (3MA) induced the short-term retardation of DCX/FF-induced
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inhibition of DU145_DCX20 motility at the single cell (Figure 5A) and population level (Figure 5B).
Because 3MA is an inhibitor of autophagy in energy-depleted cells [21], these observations suggest
that DCX/FF induces their “suicidal” autophagy. However, intensified autophagy was also seen in
DCX-resistant cells that have undergone long-term (72 h) DCX/FF treatment (Figure 5C). Thus, a small
sub-population of DU145_DC20 cells can activate "protective" autophagy in response to FF-induced
ATP deficit, which determines cell survival upon DCX/FF treatment. Its protective effect is not
strong enough to fully counteract the cytotoxic effects of DCX/FF, as illustrated by disorganization
of microtubules (cf. Figure 4) and nuclear distortions (Figure 5D) in DCX/FF-treated DU145_DCX20
cells. On the other hand, a less pronounced apoptosis (Figure 5E) and the induction of polyploidy
(Figure 5F,G) in DCX/FF-treated DU145_DCX20 cells (compared to naïve DU145 cells) indicated that
long-term DCX treatment might have induced a certain level of DCX/FF-resistance in DU145 cells.
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2.6. Long-Term DCX/FF Treatment Does Not Prompt the Microevolution of DCX/FF-Resistant DU145 Cells
To further elucidate whether the combined DCX/FF treatment can prompt the microevolution
of the DCX/FF-resistant cells, we subjected naïve DU145 cells to the long-term DCX/FF exposition
protocol (Figure S3; see Section 4 Materials and Methods). This allowed us to establish an epithelioid
cell line (DU145_DCX/FF), characterized by the motility, invasive potential in vitro and DCX-resistance
of DU145_DCX/FF cells were similar to these of DU145_DCX20 cells (Figure 6A). Interestingly, these
cells retained relatively high susceptibility to the combined DCX/FF treatment, as illustrated by
their considerably inhibited proliferation (Figure 6B) and the motility similar to that estimated for
DU145_DCX20 cells in corresponding conditions (Figure 6C; cf. Figure S8A). Concomitantly, the
magnitude of their apoptotic response to combined DCX/FF treatment was similar to that observed
in DU145_DCX20 populations (Figure 6D, cf. Figure S8B). Collectively, these observations indicate
that long-term exposure of DU145 cells to DCX/FF does not prompt their resistance to combined
DCX/FF treatment.
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Figure 6. Long-term DCX/FF treatment of prostate cancer cells does not prompt their
DCX/FF-resistance. (A) DCX-resistance and phenotypic properties of DU145_DCX/FF cells.
DU145_DCX/FF c lls were cultivated in the presence of DCX (cf. Figure 2A) and their proliferation was
compared to the proliferation of DU145_DCX20 cells (upper left). Concomitantly, actin cytoskeleton
architecture (upper right), motility (lower right) and proliferation (lower left) was estimated in the
absence of chemotherapeutics. (B) DU145_DCX/FF cells were incubated in the presence of DCX
(0.6-10 nM) and/or FF (25 µM) and their proliferatio was estimated after 48 h. (C) Motility of
DU145_D X/FF cells cultivated in th presence of DCX (2.5 nM) and or FF (25 µM) for 48 h, plotted
as percent of DU145_DCX20 control. Column charts show movement parameters at the population
level. (D) Comparison of apoptotic responses of DU145_DCX20 and DU145_DCX/FF cells to the
combined DCX/FF treatment (cf. Figure S8). (E,F) Sensitivity of DU145, DU145_ CX20./50 and
DU145_DCX/FF cells to FF, stima ed with proliferation (E) and motility tests (F). Data representative
of at least three independent experiments (N > 3). Statistical significance was analyzed with t-Student
test vs. non-treated DU145 control (B; * p ≤ 0.05) or DCX-treated DU145 control (A), non-treated
DU145_DCX/FF control (B) and with the variants indicated by the brackets (# p ≤ 0.05). Error bars
represent SEM. Scale bars: 50 (A) and 100 µm (E). Note the sensitivity of DU145_DCX/FF cells to
combined DCX/FF treatment and the retardation of DU145_DCX/FF cell growth in control conditions.
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Instead, we observed a correlation between DCX-resistance of prostate cancer cells and their
sensitivity to FF. It is manifested by a much stronger inhibition of their proliferation in the presence of
FF (Figure 6E). High sensitivity of DU145_DCX20/50 and DU145_DCX/FF cells to FF treatment is
also illustrated by a considerable inhibition of motility in the presence of FF (Figure 6F, cf. Figure S8C).
Together with their relatively slow proliferation rate in control conditions, these data demonstrate
that DCX-resistance implies metabolic reprogramming of prostate cancer cells that increases their
sensitivity to FF, interferes with their propagation in the presence of FF, and impairs the microevolution
of “super-resistant” cells.
3. Discussion
According to Hanahan and Weinberg, the basic hallmarks of cancer include the replicative
immortality of cancer cells, their resistance to growth suppressors and pro-apoptotic signals, and
overactive proliferative signaling [22,23]. These features underlie a rapid and tissue-independent
expansion of cancer cells and the hyperplasia/hypertrophy of primary tumors. Both processes
are further facilitated by reprogramming of energy metabolism and the pro-angiogenic potential
of cancer cells. Together with tumor cells’ invasiveness and immunoresistance, these hallmarks
enhance the micro-environmental adaptability of cancer cells and their capability of colonizing
new “niches”. Till now, the interference of fenofibrate (FF) with the malignancy of tumor cells was
predominantly considered in terms of its cytostatic, pro-apoptotic and anti-invasive activity [24–28].
Only a few studies have considered the synergy of cytostatic effects of FF and chemotherapeutic
drugs [29,30]. Our study is the first to scrutinize the anti-cancer potential of fenofibrate in the
context of the microevolution of drug-resistance in prostate cancers. It shows that the interference
of FF with P-gp-dependent efflux systems in drug-resistant prostate cancer cells can increase their
sensitivity to chemotherapeutics, including docetaxel and mitoxantrone. Next, we demonstrate that the
microevolution of drug-resistance can increase cellular sensitivity to the cytostatic effect of fenofibrate.
Both these effects potentially can impair the microevolution and progression of drug-resistant prostate
tumors in vivo. Notably, these effects were observed in the presence of <25 µM FF, i.e., within the
range of its tolerable serum concentrations (up to 100 µM, [31]). This confirms the potential of FF for
application in the palliative treatment of drug-resistant prostate tumors.
Chemotherapy usually leads to a transient syndrome relief, but the selective pressure exerted
by chemotherapeutics promotes the Darwinian “survival of the fittest” cells. Drug-resistant
cell sub-populations, incl. the “cancer stem cells” (CSCs; [5,6,9,10,32–36]), can pre-exist in the
heterogeneous populations of prostate cancer cells [37–39]. Alternatively, adaptive phenotypic shifts,
for instance the incomplete (type III) EMT-related transitions, favor the microevolution and selective
expansion of the drug-resistant cells during prostate cancer chemotherapy [40]. To imitate this process
in vitro, we used the approach based on the long-term “adaptive” exposition of prostate cancer DU145
and PC3 cells to chemotherapeutics. It resulted in the establishment of cell lineages that display high
resistance to DCX and MTX. Notwithstanding the mechanism underlying their microevolution under
DCX stress, FF interferes with the drug-resistance of prostate cancer cells as illustrated by additive
attenuating effects of combined DCX/FF treatment on their expansion. This effect is executed by
the induction of “suicidal” autophagy in DCX/FF-treated cells, which is followed by their apoptosis.
It stays in concordance with the previous reports on the cytostatic FF activity [18]. Concomitantly, we
have showed a long-term interference of the combined DCX/FF treatment with the displacement and
diapedesis efficiency of drug-resistant cells. All these processes govern the selective recruitment of
drug-resistant cancer cells to the invasive tumor fronts in vivo and their malignancy [19,41]. Thus, our
current data are perhaps the first to directly show that FF can be used in the metronomic approaches
of drug-resistant prostate tumors’ treatment.
In our hands, the activation of P-gp (ABCB1) transporter accounted for a stable
DCX/MDX-resistance of DU145 and PC3 cells that have undergone long-term DCX treatment.
The efficiency of this system is illustrated by the relatively high viability and proliferation rate of
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DCX/MTX-treated DU145_DCX20/50 cells and by their sensitivity to the combined DCX/elacridar
treatment. The attenuation of calcein efflux, observed in drug-resistant cells upon FF administration,
demonstrates the interference of FF with ATP/P-gp-dependent DCX efflux system. The interference of
FF with P-gp function has previously been reported in naïve tumor cells [42]. Apparently, it results in
an intensified influx of DCX to DCX/FF-treated DU145 and PC3 cells, as confirmed by the disruption of
microtubules and the induction of prostate cancer cell polyploidy. Thus, we show that FF interferes with
drug-resistance, which has been acquired during their adaptive, DCX stress-induced microevolution.
Similar cytostatic effects of FF on drug-resistant prostate cancer cells were observed in the presence
of MTX. These FF activities were insensitive to chemical PPARα inhibition and ROS scavenging.
It demonstrates that PPARα-/ROS-dependent signaling systems [24,25,43–48] are not involved in cell
reactions to FF, even though the inhibition of DU145 proliferation by PPARα inhibition shows the
significance of PPARα for the welfare of prostate cancer cells. We also ruled out the involvement
of Cx43-mediated “by-stander effects” [49], because the inhibition of residual GJIC was observed
in DCX/FF-treated DU145 populations, whereas PC3 cells are connexin-negative [38]. In turn, we
observed lower ATP levels in DCX/FF-treated cells than in their DCX/elacridar-treated counterparts.
This demonstrates that FF evokes energy deficit in prostate cancer cells. A corresponding effect has
previously been described in glioblastoma cells, where FF impaired mitochondrial respiration at the
level of complex I of the electron transport chain [50].
Until now, the research on the additive cytostatic effects of FF and chemotherapeutics was focused
on the analysis of the synergy of their effects on naïve cancer cells. We are the first to comprehensively
address the consequences and mechanisms of FF interference with acquired drug-resistance of prostate
cancer cells. Collectively, we show a PPARα/ROS-independent interference of FF with the energy
production in DCX-resistant cells, which leads to the inhibition of ATP/P-gp-dependent efflux
system(s). Consequently, DCX, MTX and, potentially, other chemotherapeutics are accumulated
inside the cells. Their interference with microtubular dynamics, with the intracellular P-gp transport
(DCX, paclitaxel) or with P-gp synthesis (MTX) can lead to the further impairment of P-gp function
and the intensification of DCX/MTX influx. Apparently, this vicious cycle results in the intoxication,
mitotic catastrophe, and apoptosis of drug-resistant cells. The interference of FF with the energy
production may also have profound consequences for the microevolution of drug-resistant prostate
tumors. Actually, the cells that had survived the permanent DCX/FF-induced stress gave the offspring
(DU145_DCX/FF lineage) that displayed relatively high DCX/FF sensitivity and a benign phenotype.
A correlation between the resistance of DU145 and PC3 cells to DCX and MTX, and their sensitivity to
FF suggests that oxidative respiration is intensified in drug-resistant DU145/PC3 lineages [51]. It may
well be that DCX- and DCX/FF-induced metabolic reprogramming increases ATP supply in cancer
cells to ascertain the efficient action of efflux pumps [50]. However, metabolic reprogramming can also
be an Achilles heel of drug-resistant cancer cells, because it sensitizes drug-resistant cells to FF-induced
imbalance between ATP demand and supply. Its precise mechanism(s) and clinical consequences
require further study. However, these observations may illustrate a novel mechanism that underlies
the interference of FF with the microevolution of drug-resistant prostate cancers, which potentially
leads to the remission of drug-resistant tumors in vivo.
Further studies are also necessary to estimate the involvement of other drug-resistance
mechanisms in cell reactions to DCX/FF-induced stress. In fact, the activation of FF-insensitive
self-defense systems in DCX/FF-treated cells is suggested by their relatively weak apoptotic response
to the combined DCX/FF treatment. “Suicidal” autophagy in DCX/FF-treated cells was followed by
its “protective” variant in scarce cell sub-populations, which have survived the long-term DCX/FF
treatment. FF may interfere with this process [52,53]; however, autophagy can confer survival
advantage to scarce sub-populations of DCX/FF-treated drug-resistant cancer cells. Furthermore, the
presence of CD133+/CD44+ CSC-like cells within the populations of drug-resistant cells (data not
shown) was accompanied by a relatively high fraction of polyploid, polymorphonuclear “giant” cells
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in their DCX/FF-treated variants [54]. It indicates that these cells may account for the clonal expansion
of CSCs [55,56] that underlies the microevolution of prostate cancer cell lineages under DCX/FF stress.
Drug-resistance of cancer cells is a major challenge of current oncology. Therapeutic approaches of
palliative prostate cancer treatment should be systemically tolerable and efficient against drug-resistant
cancers. They should also interfere with the invasive front of cancer and with the microevolution of
drug-resistant cells. Currently available chemotherapeutic strategies provide some symptom relief but
are incapable of effectively interfering with the natural history of hormone-refractory prostate cancer.
Usually, drug-resistance is developed in prostate tumors subjected to chemotherapy-related stress,
following their castration-resistance. Concomitantly, chemotherapeutics evoke a number of adverse
effects, which limit their long-term application and often enforce premature cessation of palliative
chemotherapy, leading to inevitable and lethal relapses. Metronomic strategy based on the combined
application of cytostatics (DCX or MTX) and fenofibrate can interfere with the drug-resistance of
prostate cancer cells in vivo, thus reducing the effective doses of chemotherapeutics. It can also
delay the metastatic cascade of prostate cancers. Furthermore, it can delay chemotherapy-induced
microevolution, expansion and systemic dissipation of drug-resistant, invasive sub-clones of prostate
cancer cells. Last but not least, FF has previously been shown to interfere with tumor angiogenesis
and to augment endothelial barrier function [38,57,58]. Therefore, FF is a promising metronomic agent
that can serve to enhance the efficiency of the palliative chemotherapy of prostate cancer. On the other
hand, we have also detected the signs of DCX/FF resistance of prostate cancer cells. It may well be
that prostate cancer cells can activate FF-insensitive, drug-resistance mechanisms that protect them
against DCX/FF-induced stress in vivo. Such mechanisms include drug efflux-independent systems
based on autophagy and/or on the function of polyploid “giant” cells, which may participate in tumor
recurrence after the cessation of chemotherapy. Furthermore, it remains to be determined if FF can
interfere with the drug-resistance of other tumors. The data from in vitro studies cannot be directly
interpreted in terms of the clinical application of tested agents. Therefore, all these assays should also
be performed on the cells from clinical samples and should be accompanied by epidemiologic studies
on the interference of FF with prostate cancer progression. Nevertheless our data, in conjunction
with the relatively high systemic tolerance of fenofibrate, suggest that FF can help to overcome basic
limitations of chemotherapy in the treatment of elderly prostate cancer patients [29]. Thus, they add to
the wide spectrum of cytostatic and anti-invasive activities of this FDA-approved drug [17,59].
4. Materials and Methods
4.1. Cell Cultures
Human prostate carcinoma DU145 (ATCC; HTB-81), PC3 cells (ECCAC; HTB-81) and their
drug-resistant sub-lineages were routinely cultivated in DMEM/F12 HAM (Sigma, St. Louis, MO)
medium supplemented with 10% fetal bovine serum (FBS) and antibiotics [19,38]. Human umbilical
vein endothelial cells (HUVEC; Life Technologies Corporation, Carlsband, CA, USA) were cultured
(up to six passages) in endothelial basal medium (EBM; Lonza, Basel, Switzerland) supplemented with
10% fetal bovine serum (FBS) and supplement cocktail (hydrocortisone, recombinant hEGF, bovine
brain extract, gentamicin, amphotericin-B; all from Lonza [58]). For endpoint experiments, media
supplemented with DCX and/or FF were added to cancer cell cultures at the concentrations given
in the text. Culture media were supplemented with: docetaxel (DCX; 0.125–50 nM), mitoxantrone
(MTX; 62.5–2000 nM) and/or fenofibrate (FF; 5–25 µM; F6020, Sigma, Saint Louis, MO, USA), GW6471
(10 µM; G5045), N-acetyl-L-cysteine (NAC; 1 mM; A9165, Sigma), elacridar (100 nM); sulfinpyranoze
(500 µM), Fumitremorgin C (10 µM), 3-methyladenin (3MA; 0.5 µM; all from Sigma) at the time points
indicated in the text. Chemical inhibitors were administrated at the time points indicated in the text
and at the concentrations that secure their specific action and the lack of cytotoxic effects.
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4.2. Establishment of DCX-Resistant DU145 Sub-Lineages
Prior to a pre-selection procedure, dose-response assay was performed to estimate the range of
DCX concentrations that significantly inhibits the growth of naïve DCX145 and PC3 cells over a 3-day
treatment. Because the treatment of DU145 cells with 1 nM DCX resulted in ca. 30% growth retardation,
a selection strategy of cell exposure to DCX was initiated with the media supplemented with 1 nM DCX.
Cells were seeded at the density of 2 × 104 cells/cm2 into 6-well plates. The media were replenished
after 3 days with the fresh medium containing 30% of DU145-conditioned medium to allow the cells to
recover from chemotherapeutic stress, and the cells were cultivated in its presence for 3 days before a
new portion of 1 nM DCX-containing medium was administered. After 3 cycles of therapy/recovery,
the procedure was repeated in the presence of higher DCX concentration (Figure S3). To establish
DU145_DCX20 cell line, DCX was sequentially applied at the concentrations of 1, 2, 5, 10, 20 nM.
A corresponding procedure was employed to establish PC3_DCX20 cells. Additionally, DU145_DCX20
cells were subjected to 3 cycles of 50 nM DCX treatment to establish DU145_DCX50 cells. Alternatively,
DU145 were consecutively cultivated in the presence of increasing DCX/FF concentrations to establish
“super-resistant” DU145_DCX/FF sub-lineage. The following DCX/FF concentrations (nM/µM)
were sequentially applied: 1/2.5, 2/5, 5/10, 10/20, 20/25. Since the continuous cell culture can
result in alterations in cellular characteristics (including drug-resistance), untreated parental cells
were cultivated alongside the treated cells as a control. The established subsets and sub-clones were
cultivated in standard medium for ca. 15 generation times (five passages at 1:8). Stability of acquired
resistance was assessed after freezing, thawing and following drug withdrawal throughout this period.
4.3. Cell Motility and Transmigration Assays
The movement of cancer cells was recorded using time-lapse Leica DMI6000B videomicroscopy
system equipped with a temperature chamber (37 ◦C ± 0.2 ◦C)/(5% CO2), interference modulation
contrast (IMC) optics and a cooled, digital DFC360FX CCD camera. DU145 and PC3 cells were seeded
into 12-well plates at a density of 5000 (short-term incubation variant) or 1000 cells/cm2 (long-term
incubation variant). The cell trajectories were constructed from a sequence of cell centroid positions
recorded for 6 h at 300 s time intervals (using a dry ×10, NA-0.75 objective) to estimate: total length of
single cell trajectory (µm), speed of cell movement (i.e., total length of single cell trajectory/time of
registration (µm/min) and total length of single cell displacement (Displacement; µm). These data
were pooled and analyzed to calculate the averaged values of these parameters at the population level
and to perform their statistical analysis (from no less than three independent experiments; number
of cells >50 [60]). For transmigration assays, human umbilical vein endothelial cells (HUVEC) were
seeded on coverslips at 2 × 104 cells/well and grown to confluence for 72 h. Thereafter, CellTracer
Orange CMRA (10 µM, Life Technologies)-stained cancer cells were seeded (1300/cm2) on HUVEC
monolayers and incubated for 1 and 6 h [58]. Then, the specimens were stained against F-actin/DNA
for microscopic estimation of the percentage of cancer cells capable of disrupting the endothelial
continuum (transmigration). Transmigration of at least 200 cancer cells was analyzed for each group.
4.4. Calcein Transfer Assay
Donor and acceptor cells were incubated in the presence of 2.5 nM DCX/25 µM FF for 24 h.
Donor cells were stained with calcein/DiI (Life Technologies; C3099; 5 µM/10 µM) as described
previously [61] and seeded onto the monolayers of acceptor cells at 1:50 ratio. After 1 h, a dye transfer
from at least 200 donor cells per coverslip was analyzed using a Leica DMI6000B inverted fluorescence
microscope (Leica; excitation—BP 470/40 nm; emission—BP 525/50) equipped with LasX software.
It was further quantified as the percentage of donor cells, which successfully coupled with acceptor
monolayer (coupling index; ci) and averaged number of coupled acceptor cells/a donor cell (coupling
ratio; cr). Alternatively, co-cultures of donor and acceptor cells were trypsinized and fluorescence
intensity of suspended cells was measured with a fluorescence-activated cell sorting (FACS) Aria
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system (Becton–Dickinson, Heidelberg, Germany; excitation wavelength of 488 nm). The emission of
calcein and DiI was determined after filtering with a 530/30-nm (FL1) and a 575/26-nm bandpass filter
(FL2), respectively. Each sample was measured three times at a total of 10 000–50 000 cells. GJIC was
further quantified as the ratio of calcein stained acceptor to donor cells (coupling ratio). 3 independent
experiments (N = 3) were performed for each experimental condition.
4.5. Immunofluorescence
Immunostaining of α-tubulin and vinculin was performed on formaldehyde/Triton X-100
fixed/permeabilized cells (FA; 3.7%; 20 min. in RT)/Triton X-100 (0.1%; 10 min. in RT). Intracellular
Cx43 and P-gp localization was visualized in the cells fixed with methanol:acetone (7:3, −20 ◦C) for
15 min. After the incubation in the presence of 3% bovine serum albumin (BSA), primary antibodies:
rabbit anti-Cx43 IgG (No. C6219, Sigma), mouse anti-vinculin IgG (No. V9131, Sigma), mouse
anti-α-tubulin IgG and mouse anti-P-gp IgG (all from Sigma) were applied for 1 h. Then, the cells
were labeled with Alexa 488-conjugated goat anti-mouse IgG (No. A11001, Invitrogen, Carlsbad, CA,
USA), Alexa 488-conjugated goat anti-rabbit IgG (A11008, Invitrogen). Where indicated, the cells
were counterstained with Alexa488 or TRITC-conjugated phalloidin (No. 49409 and 77418, Sigma)
and Hoechst 33258 (No. B2883, Sigma) or 7AAD (No 51-2359KC, BD Pharminogen, San Diego, CA,
USA) [38]. Image acquisition was performed with a Leica DMI6000B microscope (DMI7000 version;
Leica Microsystems, Wetzlar, Germany) equipped with the total internal reflection fluorescence (TIRF)
and differential interference contrast (DIC) and integrated modulation contrast (IMC) modules. Images
were registered with 40×, NA-1.47 oil immersion objective in 37 ◦C/5%CO2 using 14-bit Hamamatsu
9100-02 EM-CCD camera controlled by the Leica Application Suite Advanced Fluorescence software.
LAS-AF deconvolution software was used for image processing [39].
4.6. Proliferation, Cell Cycle and Apoptosis Assays
Cells were seeded in triplicates into 24-well plates (Corning) at the density of 5 × 103 cells/cm2,
cultivated in the culture medium for 24 h, before the addition of the media containing DCX/FF and/or
the inhibitors. After 48 h of cultivation, the cells were harvested and re-suspended in the original
culture medium. Counting was performed with a Coulter Z2 Counter (Beckman Coulter Inc., Fullerton,
CA, USA). Doubling times (DT) were calculated according to the formula: DT=Tln2/ln(Xe/Xb), where:
T is the incubation time; Xb and Xe are the cell numbers at the beginning and at the end of the
incubation time, respectively.
For DNA content (cell-cycle) analyses, the cells were seeded into 6-well plates (Corning)
at the density of 5×103 cells/cm2, cultivated in culture medium for 24 h. Thereafter, media
containing FF (25 µM) and/or DCX (2.5 nM) were administered for 48 h, followed by their collection,
trypsinization of the attached cells, and their resuspension in the original medium, fixation with
EtOH (70% at −20 ◦C) and propidium iodide staining (PI; 50 µg/mL) in the presence of RNAseA
(1 mg/mL). FlowSight®imaging cytometer (Amnis Corp., Seattle, WA, USA) was employed for the
analyses of DNA content. At least 3x105 cells were analyzed for each condition. Concomitantly,
the attached cells were fixed with EtOH (70% at −20 ◦C), stained with Hoechst33258 (Sigma,
1 µg/mL) and the morphology of their nuclei was analyzed with fluorescence microscopy. For
the analyses of cell apoptosis, trypsinized cells were re-suspended in original medium and subjected to
AnnexinV/propidium iodide staining according to the manufacturer’s protocol (BD Pharmigen). Flow
cytometric detection of apoptotic cells was performed with a FACSAria system (Becton–Dickinson,
Heidelberg, Germany [62]. At least 5x104 cells were analyzed for each condition.
4.7. Intracellular Adenosine Triphosphate (ATP) Assay
Intracellular ATP contents were estimated using luminescence ATPlite detection assay system
(cat. no. 6016947; Perkin-Elmer, Warszawa, Poland) according to the manufacturer’s protocol. Briefly,
the cells were cultivated in the presence of DCX/FF/elacridar for 48 h, lysed and the equal volumes of
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cell lysates were transferred to white plates for collection of luminescence signals using the Infinite
M200 reader. ATP contents per population/cell were estimated from calibration curves to estimate
the effect of the agents on cell viability and on the efficiency of ATP production at the single cell and
population level.
4.8. Analyses of DCX-Resistance of DU145 Cells in Vivo
Severe combined immunodeficient (SCID) mice of ages 5 weeks were purchased from Charles
River Laboratories and maintained in a temperature-controlled, pathogen-free room. Before the
experiments, the animals were quarantined and acclimatized for two weeks. Mice were kept in
community cages on a standard laboratory diet with free access to drinking water and a 12 h
day/night regime. All animals were handled according to the approved protocols and guidelines
of 2nd Local Ethics Committee for Experiments on Animals at the Jagiellonian University in Cracow
(Dec No. 290/2017). Cancer cells were mixed with BD Matrigel basement membrane matrix high
concentration (1:1 in PBS; BD Biosciences), and 40 µL of the cold liquid Matrigel-mixed (1.5 × 105)
cells was slowly injected subcutaneously into abdominal flank of SCID mice. The mice were observed
for 3 to 5 weeks for the appearance and development of tumors. Every 4 days, docetaxel (20 mg/kg)
was administrated intraperitoneally to the mice. The tumor volume was calculated according to
the following formula: V = (Π/6)a×b×c, where a, b, c are perpendicular diameters of the ellipsoid
approximating the shape of the tumor.
4.9. Tandem Mass Spectrometry
Tandem mass spectrometry (liquid chromatography–mass spectrometry, LC–MS/MS) was
performed with the reversed-phase liquid chromatography (RPLC) system (UltiMate 3000 RSLCnano
System, Thermo Fisher Scientific, Waltham, MA USA) coupled Q-Exactive mass spectrometer (Thermo
Scientific); mass spectrometer. Lysates of DU145 cells and their DCX-resistant counterparts cells were
prepared for shotgun LC–MS/MS measurements using the filter assisted sample preparation (FASP)
method. The peptide samples were loaded onto a trap column (Acclaim PepMap 100 C18, Thermo
Fisher Scientific) and further separated on analytical column (Acclaim PepMap RSLC C18, Thermo
Fisher Scientific). Eluting peptides were ionised using a Digital PicoView 550 nanospray source (New
Objective) and acquired in a MS data dependent mode using top twelve method. The LC–MS/MS data
were analyzed using Proteome Discoverer 1.4 and a MASCOT server against the Swissprot_201802
database. Search result validation was performed using the Percolator algorithm.
4.10. Calcein Efflux Assay
For the calcein-AM efflux assay, cells were detached by trypsin/EDTA treatment, re-suspended in
0.25 µM calcein-AM solution in PBS and incubated for 30 min. at 37 ◦C. Then, the cells were washed
and splitted to quantify P-gp activity by fluorescence microscopy or flow cytometry. Flow cytometric
detection of calcein fluorescence was performed with BD LSR Fortessa X-20 flow cytometer, using
488 nm excitation and a 525 nm band pass filter. For each analysis, 10,000 events were recorded,
according to a particle diameter exceeding 8µm. For the fluorimetric analyses of calcein-stained
specimens, the stacks of fluorescence images of at least 16 randomly chosen confluent culture regions
were collected in the green channel (A4; excitation—BP360/40 nm; emission—BP470/40 nm). In each
experiment, the stacks were obtained with the same excitation/exposure settings (excitation/camera
gain/time of exposition). The fluorescence index was estimated for each stack with LasX software
(Leica) and calculated for each specimen [63].
4.11. Analyses of Autophagy
Cells were seeded into 12-well plates (Corning) at the density of 5 × 103 cells/cm2 and cultivated
in culture medium for 24 h, before the administration of the media containing FF (25 µM) and/or DCX
(2.5 nM) for 48 h. After the incubation, the cells were treated with an Autophagy Assay Kit (MAK138,
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Sigma) according to the manufacturer’s protocol. Fluorescence intensity was measured at 360/520
nm wavelengths (excitation/emission respectively) with 40×, NA-1.47 oil immersion objective in
37 ◦C/5%CO2 and 14-bit Hamamatsu 9100-02 EM-CCD camera controlled by the Leica Application
Suite Advanced Fluorescence software.
4.12. Statistical Analysis
All data were expressed as mean ± SEM from at least three independent experiments (N = 3).
The statistical significance was tested with t-Student and Mann-Whitney tests. Statistical significance
was shown at *,# p ≤ 0.05.
5. Conclusions
Drug-resistance is a major obstacle in prostate cancer treatment. Collectively, our data show that
fenofibrate sensitizes drug-resistant prostate cancer cells to chemotherapeutics via the inactivation
of their ATP-dependent drug-efflux systems. This effect conceivably results from the interference of
fenofibrate with the energy metabolism of cancer cells and does not induce the microevolution of
their fenofibrate-resistant lineages. This novel PPARα/ROS-independent mechanism of fenofibrate
cytotoxicity opens perspectives for elaboration of new metronomic strategies of prostate cancer
treatment that would target the energy metabolism/drug-resistance of cancer cells.
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